Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 19/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737014 | 0.88 | HDAC1 (0.77) | HDAC1HDAC2HDAC3 | |
| SCHEMBL13739084 | 0.86 | HDAC1 (0.57) | HDAC1HDAC2HDAC3 | |
| SCHEMBL29371288 | 0.81 | HDAC1 (0.59) | HDAC1HDAC2HDAC3 | |
| SCHEMBL196444 | 0.81 | HDAC1 (0.59) | HDAC1HDAC2HDAC3 | |
| SCHEMBL13735532 | 0.81 | HDAC1 (0.72) | HDAC1HDAC2HDAC3 | |
| Ammonia Solution, Strong SCHEMBL21835779 | 0.80 | HDAC1 (0.58) | HDAC1HDAC2HDAC3 | |
| SCHEMBL651437 | 0.79 | HDAC1 (0.67) | HDAC1HDAC2HDAC3KCNH2 | |
| SCHEMBL1067257 | 0.78 | ABCB1 (0.63) | HDAC1HDAC2HDAC3 | |
| SCHEMBL1067260 | 0.78 | ABCB1 (0.63) | HDAC1HDAC2HDAC3 | |
| SCHEMBL651882 | 0.78 | HDAC1 (0.57) | HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4093730-B1 | HDAC DEGRADER | UNIV LEICESTER (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-2970107-B1 | PHOTOSWITCHABLE HDAC INHIBITORS | MASSACHUSETTS GEN HOSPITAL (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230120211-A1 | HDAC Degrader | UNIVERSITY OF LEICESTER (GB) | 2023-04-20 | — | — | US | disclosed |
| US-11596691-B2 | Photoswitchable HDAC inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220033388-A1 | HDAC1,2 Inhibitors | REGENACY PHARMACEUTICALS, LLC | 2022-02-03 | — | — | US | disclosed |
| EP-3863631-A1 | PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS | Regenacy Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3856174-A1 | HDAC1,2 INHIBITORS | Regenacy Pharmaceuticals, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007100657-A2 | INHIBITORS OF HISTONE DEACETYLASE | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007082873-A1 | HETEROCYCLYLALKYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007061978-A1 | SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061880-A1 | SPIROCYCLIC COMPOUNDS AS HDAC INHIBITORS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117824-A1 | Spirocyclic compounds | MERCK SHARP & DOHME LLC | 2007-05-24 | — | — | US | disclosed |
| EP-1663953-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030705-A9 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005030705-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542242-B2 | Substituted piperazines as selective HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC2 2/4885HDAC3 8/4885 |
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 7/4885 |
| US-20230120211-A1 | HDAC Degrader | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC2 4/4885HDAC3 3/4885 |
| US-11858919-B2 | HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC2 2/4885HDAC3 6/4885 |
| US-20220033388-A1 | HDAC1,2 Inhibitors | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC2 2/4885HDAC3 6/4885 |
| US-20070117824-A1 | Spirocyclic compounds | BRDT, TXNRD3, HDAC1 | HDAC1 3/4885HDAC2 8/4885HDAC3 10/4885 |
| US-11596691-B2 | Photoswitchable HDAC inhibitors | HDAC4, HDAC1, HDAC3 | HDAC1 2/4885HDAC2 7/4885HDAC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.